Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00776191
Other study ID # 2005-005434-12
Secondary ID
Status Terminated
Phase Phase 4
First received October 20, 2008
Last updated June 3, 2015
Start date September 2008
Est. completion date May 2012

Study information

Verified date June 2015
Source University of Erlangen-Nürnberg Medical School
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate an increase in protein metabolism during treatment with Physioneal 35® (containing lactate 10 mmol/l, calcium 1.75 mmol/l) compared to treatment with Physioneal 40® (containing lactate 15 mmol/l, calcium 1.25 mmol/l) in children and adolescents with end stage renal failure receiving peritoneal dialysis.


Description:

- Fat oxidation (13C-enrichment in expiration breath samples for U-C13-algae turnover)

- Growth markers (plasma levels of IgF-1, IgF-BP3, leptin)

- Biochemical markers of anabolism (plasma levels of total protein, albumin, transferrin)

- Serum thyroid function (fT3, fT4, TSH)

- Serum lipid status

- Serum markers of calcium/phosphate metabolism (PTH, calcium, ionized calcium, phosphate, alkaline phosphatase)

- Prevalence of metabolic acidosis/ alkalosis (venous sample), serum lactate

- Safety parameters (such as normalized weekly Kt/v, parameters of glucose metabolism, parameters of hepatic function, parameters of calcium-phosphate-metabolism, physical examination incl. standing height, weight, assessment of complications related to peritoneal dialysis as peritonitis, exit infections and inguinal hernia)

- Body composition (lean body mass and body fat mass/fluid)


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date May 2012
Est. primary completion date May 2012
Accepts healthy volunteers No
Gender Both
Age group 3 Months to 18 Years
Eligibility Inclusion Criteria:

- Patients who are males or non-pregnant females between the ages of 3 months and 18 years.

- Patients who are on regular automated peritoneal dialysis due to end stage renal failure for at least 3 months.

- Patients and/or their parents must be capable of understanding the purpose and risks of the study.

- Patients and/or their parents (or guardians) who are willing to give written informed consent and willing to participate in and comply with the study protocol.

Exclusion Criteria:

- Use of pure lactate, amino acid or oligosaccharide solutions for peritoneal dialysis

- Peritonitis episode less than 6 weeks before enrolment

- Hypercalcemia (serum) > 2.75 mmol/l in three independent measurements during 10 days

- Severe secondary hyperthyroidism (iPTH > 500 ng/l)

- Renal anemia with hemoglobin (blood) < 10 mg/dl

- Impaired hepatic function (AST/SGOT or ALT/SGPT > 2 times the upper limit of the reference range)

- Patients who are participating in another study that requires Ethics Committee approval. Non-interventional studies are permitted.

- Pregnant female patients, females of childbearing potential who are unwilling or unable to use adequate contraception methods.

- Severe respiratory insufficiency

- Malnourishment (body weight < -2.5 SDS for height and gender) or severe deterioration of fat metabolism

- Patients with a history of malignancy of any organ system, treated or untreated

- Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of the investigational product and the comparator, including

- Major deterioration of the abdominal wall (e.g. dermal infections or burns, hernia)

- Major deterioration of the abdominal cavity (e.g. ascites, ileus, adhesions, bowel perforation, defects of the diaphragm, tumours)

- Patients with a history of viral infections such as HIV or hepatitis B, C.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Physioneal 35
Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
Physioneal 40
Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks

Locations

Country Name City State
Germany Pediatric Nephrology, Universiy Children's Hospital Cologne
Germany Dept. of Pediatric Nephrology, University Hospital Erlangen Erlangen
Germany Dept. of Pediatric Nephrology, University of Hannover Hannover
Germany Dept. of Nephrology, children´s hospital Memmingen Memmingen
Germany Dept. of Nephrology, University of Rostock Rostock

Sponsors (1)

Lead Sponsor Collaborator
University of Erlangen-Nürnberg Medical School

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary To demonstrate an increase in protein metabolism during treatment with Physioneal 35® compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. 16 weeks Yes
Secondary To demonstrate a improved Fat oxidation during treatment with Physioneal compared to treatment with Physioneal 40® in children and adolescents with end stage renal failure receiving peritoneal dialysis. 16 weeks Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03023748 - Intravenous Paricalcitol in Chronic Hemodialysis Patients Phase 4
Completed NCT00745914 - Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) Agonist in Diabetic End-Stage Renal Disease Patients N/A
Completed NCT02981706 - Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis N/A
Completed NCT02946229 - Data Collection for Next Generation Ultrasound Technology Development N/A
Completed NCT02976246 - Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients Phase 4
Completed NCT02966028 - Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) Phase 2
Recruiting NCT02957877 - LMWH Infusion as Anticoagulation for Home HD Phase 4
Completed NCT00745719 - Parathyroidectomy in Endstage Renal Disease N/A
Completed NCT03010072 - The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum Phase 2
Recruiting NCT03020303 - Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease Phase 3
Completed NCT00745589 - Sevelamer Hydrochloride in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT02976688 - Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis Phase 2/Phase 3
Completed NCT02970201 - Improving Adherence in Renal Dialysis Patients Through Electronic Interventions N/A
Withdrawn NCT00502268 - Vitamin D and Carboxy PTH Fragments in Coronary Calcification Phase 4
Completed NCT02207153 - Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients
Completed NCT02977117 - The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis Phase 2
Completed NCT02866214 - Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients. Phase 2/Phase 3
Not yet recruiting NCT03054454 - A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure N/A